# Study of Pembrolizumab Maintenance Following First-Line Platinum Based Chemotherapy in Patients With Metastatic Squamous - Non-Small Cell Lung Cancer (sNSCLC)

> **NCT02564380** · PHASE2 · TERMINATED · sponsor: **AIO-Studien-gGmbH** · enrollment: 41 (actual)

## Conditions studied

- Metastatic Squamous Non-small Cell Lung Cancer

## Interventions

- **DRUG:** Pembrolizumab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02564380
- **Lead sponsor:** AIO-Studien-gGmbH
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-01-19
- **Primary completion:** 2020-05-23
- **Final completion:** 2020-11-23
- **Target enrollment:** 41 (ACTUAL)
- **Why stopped:** Since trial start in Jan. 2016 only 41 patients could be recruited until planned date of end of follow up period. Under consideration of this fact the recruitment of the planned 130 patients was not possible within a reasonable recruitment period.
- **Last updated:** 2022-01-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02564380

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02564380, "Study of Pembrolizumab Maintenance Following First-Line Platinum Based Chemotherapy in Patients With Metastatic Squamous - Non-Small Cell Lung Cancer (sNSCLC)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02564380. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*